Last reviewed · How we verify

Resuscitation (Saline)

Universidad Nacional de La Plata · Phase 3 active Small molecule ✓ Verified May 2026

Resuscitation (Saline) is a Crystalloid fluid / Electrolyte replacement Small molecule drug developed by Universidad Nacional de La Plata. It is currently in Phase 3 development for Hypovolemic shock and hemorrhagic shock resuscitation, Severe dehydration and fluid loss, Perioperative fluid management.

Saline resuscitation restores circulating blood volume and tissue perfusion by administering isotonic sodium chloride solution intravenously.

Saline is a fluid used in resuscitation, specifically in the treatment of conditions such as Out-Of-Hospital Cardiac Arrest and Postcardiac Arrest Syndrome. It is administered through various techniques, including the Push-Pull technique, as part of fluid therapy interventions.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameResuscitation (Saline)
SponsorUniversidad Nacional de La Plata
Drug classCrystalloid fluid / Electrolyte replacement
ModalitySmall molecule
Therapeutic areaCritical Care / Emergency Medicine
PhasePhase 3

Mechanism of action

Saline solution replaces lost intravascular fluid during hemorrhage, shock, or severe dehydration, thereby restoring adequate perfusion pressure and oxygen delivery to vital organs. The isotonic formulation (0.9% NaCl) maintains osmotic balance and prevents cellular edema while expanding the extracellular fluid compartment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Resuscitation (Saline)

What is Resuscitation (Saline)?

Resuscitation (Saline) is a Crystalloid fluid / Electrolyte replacement drug developed by Universidad Nacional de La Plata, indicated for Hypovolemic shock and hemorrhagic shock resuscitation, Severe dehydration and fluid loss, Perioperative fluid management.

How does Resuscitation (Saline) work?

Saline resuscitation restores circulating blood volume and tissue perfusion by administering isotonic sodium chloride solution intravenously.

What is Resuscitation (Saline) used for?

Resuscitation (Saline) is indicated for Hypovolemic shock and hemorrhagic shock resuscitation, Severe dehydration and fluid loss, Perioperative fluid management.

Who makes Resuscitation (Saline)?

Resuscitation (Saline) is developed by Universidad Nacional de La Plata (see full Universidad Nacional de La Plata pipeline at /company/universidad-nacional-de-la-plata).

What drug class is Resuscitation (Saline) in?

Resuscitation (Saline) belongs to the Crystalloid fluid / Electrolyte replacement class. See all Crystalloid fluid / Electrolyte replacement drugs at /class/crystalloid-fluid-electrolyte-replacement.

What development phase is Resuscitation (Saline) in?

Resuscitation (Saline) is in Phase 3.

What are the side effects of Resuscitation (Saline)?

Common side effects of Resuscitation (Saline) include Hyperchloremic acidosis, Fluid overload / pulmonary edema, Electrolyte imbalance.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing